These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17683706)

  • 1. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
    Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
    AIDS; 2005 Jan; 19(2):153-62. PubMed ID: 15668540
    [No Abstract]   [Full Text] [Related]  

  • 7. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
    Hill A
    AIDS; 2005 Nov; 19(17):2054-5. PubMed ID: 16260922
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
    Di Biagio A; Prinapori R; Giannarelli D; Maggiolo F; Di Giambenedetto S; Borghi V; Penco G; Cicconi P; Francisci D; Sterrantino G; Zoncada A; Monno L; Capetti A; Giacometti A;
    J Antimicrob Chemother; 2013 Jan; 68(1):200-5. PubMed ID: 22915463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.
    Cameron DW; da Silva BA; Arribas JR; Myers RA; Bellos NC; Gilmore N; King MS; Bernstein BM; Brun SC; Hanna GJ
    J Infect Dis; 2008 Jul; 198(2):234-40. PubMed ID: 18540803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
    Squires KE; Johnson M; Yang R; Uy J; Sheppard L; Absalon J; McGrath D
    J Antimicrob Chemother; 2011 Feb; 66(2):363-70. PubMed ID: 21148235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class-sparing regimens for initial treatment of HIV-1 infection.
    Riddler SA; Haubrich R; DiRienzo AG; Peeples L; Powderly WG; Klingman KL; Garren KW; George T; Rooney JF; Brizz B; Lalloo UG; Murphy RL; Swindells S; Havlir D; Mellors JW;
    N Engl J Med; 2008 May; 358(20):2095-106. PubMed ID: 18480202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(12):807-17. PubMed ID: 18020538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir: its role in HIV treatment.
    Wood R
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):785-96. PubMed ID: 19053892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
    Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
    Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK; Struble KA
    AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.